Hims & Hers’ stock took a significant hit in early trading on Tuesday, plunging 15.5% after the telehealth firm reported a disappointing first-quarter loss of $92 million, up from $50 million in the same period last year. While revenue saw a modest increase of 4% to $608 million, the company’s adjusted EBITDA fell sharply to $44 million from $91 million. The outlook for the second quarter also fell short of expectations, with revenue guidance between $680 million and $700 million, raising concerns among analysts.
This decline is particularly impactful given Hims’ recent controversies surrounding its sales of GLP-1 weight loss drugs. The company has faced legal challenges from Novo Nordisk for selling copycat versions of its Wegovy drug, leading to a strategic pivot away from these products. The transition phase may further complicate Hims’ revenue streams, especially as it seeks to stabilize its business model amid regulatory scrutiny.
For market professionals, the key takeaway is the potential volatility in Hims’ stock as it navigates its transition away from compounded drugs, which have been a significant revenue driver. Investors should monitor how the company adapts to regulatory pressures and its ability to meet revised earnings expectations in the coming quarters.
Source: cnbc.com